TrialAnnals of hematology2017

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.

Bruce D Cheson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.